Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

The conversation is about future hair loss treatments. Current treatments mentioned include finasteride, minoxidil, and RU58841, with potential future treatments like GT20029, TDM-105795, JW0061, and follicle cloning.

Stevia microneedles increased minoxidil absorption and hair growth in mice. The conversation humorously questions the applicability of these results to humans.

The conversation discusses using RU58841 with octopirox or essential oils for hair loss treatment. The user is seeking advice on which variation to try.

Hair loss treatments like spironolactone often require lifelong use to maintain results. Stopping the medication can lead to increased testosterone levels and potential hair loss.

The post discusses a 21-month treatment of hair loss using Finasteride, a 13-month treatment with Minoxidil, and a 2-month treatment with Stemoxydine. Replies suggest enhancing results by adding a micro needling pen and tretinoin to the regimen, and consider Finasteride and Minoxidil as crucial treatments.

The user is using a hair loss regimen involving 2ddr applied twice daily, tretinoin weekly, and occasionally micro-needling. They report feeling increased scalp thickness and seeing some hair growth progress.

CRISPR treatments for blood disorders have been approved, leading to discussions about its potential for treating hair loss (AGA). A study showed that editing a gene related to DHT sensitivity could lead to hair regrowth, suggesting CRISPR may eventually be used for AGA, but it's expected to be expensive and not soon available.

The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.

Gizzela is unsure about the dosage and frequency of copper peptides and asks if they can be used with Stemoxydine. They seek advice on applying these treatments together.

A 19-year-old plans to use an experimental hair loss treatment stack including micro-needling, Minoxidil, Pyrilutamide, Ketoconazole shampoo, and other unreleased compounds like PP405. Users advise against using unverified treatments and suggest sticking to proven options like Finasteride, with some recommending topical application to avoid side effects.

Minoxidil, finasteride, and RU58841 have stopped extreme hair loss and promoted regrowth over the past two months. The combination of these treatments has been effective for the user.

The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

Eirion Therapeutics is recruiting for phase 1 of ET-02 in Texas, which showed promising hair growth results in non-clinical studies. ET-02 demonstrated significantly more hair growth compared to Minoxidil.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

The conversation is about creating homemade topical melatonin for hair loss, with one person suggesting adding melatonin to stemoxydine as a potential treatment.

The conclusion of this conversation about hair loss is that the user "its_zi" has been using a combination of minoxidil, finasteride, dutasteride, and RU58841, along with microneedling, and has seen great results in regrowing hair. They plan to continue the treatment and consider a hair transplant in the future.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

The conversation discusses various hair loss treatments, with a focus on pyrilutamide, minoxidil, and alternatives to finasteride due to intolerance. Users suggest adding a DHT blocker like finasteride or dutasteride, and some recommend trying topical versions to reduce side effects.

A user's success story of improving their hair loss with treatments that include finasteride, dutasteride, minoxidil, nizoral, and dermastamping; other products that have been tried with varying results; and potential side effects.

MaximusDurkimus shares experience with 0.25mg Finasteride, Minoxidil-induced lupus, and less than 10mg RU58841 for hair loss. Plans to try 0.025% topical Finasteride with 5% Stemoxydine and possibly Tretinoin, Fluridil, or CB-03-01 in the future.

A human trial involving the use of Verteporfin as a treatment for hair loss, which has been ongoing for 119 days with an update on its progress. Treatments such as Minoxidil, Finasteride and RU58841 have also been discussed.

The post discusses a hair loss treatment routine involving dutasteride, topical finasteride, rosemary oil/onion juice/coffee solution, and stemoxydine. The user emphasizes the importance of consistency, realistic expectations, and a healthy lifestyle.

Significant hair regrowth was achieved using 0.5mg oral finasteride, a topical mix of finasteride and minoxidil, and dermastamping. Initial side effects like achy testicles were managed by adjusting the regimen.

Hair loss discussion mentions treatments Minoxidil, Finasteride, and RU58841. Verteporfin shows promise for scar/regrowth after 84 days.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

A user's hair regrowth journey involved a hair transplant and using RU58841, finasteride, and minoxidil, with side effects managed by other medications.

A user celebrating 1 year of using finasteride as a hair loss treatment, and other users discussing the progress they have seen with it.